Inhibrx Biosciences (INBX) executive compensation, 2026 proxy

Mark P. Lappe, Chief Executive Officer and Chairman of the Board of Directors, was paid $2.9M in 2025, down 38% from $4.7M the year before.

Filed
April 23, 2026
Annual meeting
June 3, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.9M-38% vs prior year
CEO Base Salary
$695,250Unchanged from prior year
CEO Transaction Bonus
$1,700,000Paid at separation anniversary
CFO Total Pay
$923,696Fiscal 2025 compensation
President Total Pay
$1,435,940Appointed April 1, 2025

How Lappe was paid

$2.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary24%Bonus59%Non-equity incentive17%All other compensation1%

Named executive officers

ExecutiveTotal
Mark P. LappeChief Executive Officer and Chairman of the Board of Directors$2,892,473
Kelly D. Deck, C.P.A.Chief Financial Officer$923,696
David J. Matly, M.B.A.President$1,435,940

What changed and why

  • $2.9MMark P. Lappe received total compensation of $2,892,473 in fiscal 2025, representing a decrease from the prior year total of $4,703,058.
  • $695KThe CEO's base salary remained unchanged at $695,250 during fiscal 2025.
  • $1.7MA transaction bonus of $1,700,000 was paid to the CEO in connection with the one-year anniversary of the separation.
  • $480KPerformance-based cash bonuses of $479,723 were earned by the CEO for fiscal 2025 and paid in early 2026.
  • $1.4MDavid J. Matly was appointed President during the year and received total compensation of $1,435,940.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.